Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
hMPV/RSV mRNA vaccine in adults 60+ years
NCT06686654Phase 2Active, not recruiting
- Sponsor
- Sanofi
- Start
- Nov 2024
- Primary completion
- Jan 2027
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of hMPV + RSV mRNA vaccine in human metapneumovirus infection (HMPV) and respiratory syncytial virus infection (RSV) (19 arms), sponsored by Sanofi. Primary endpoints: Unsolicited immediate systemic adverse events at 30 minutes, Solicited injection site and systemic reactions at 7 days and 10 more. Started Nov 2024; status: active, not recruiting.
02
Drugs
hMPV + RSV mRNA vaccine
03
Conditions
human metapneumovirus infection (HMPV)respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT06686654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06686654.